"Based on this proposal, some shifts may significantly impact the practice of urology," write Jonathan Rubenstein, MD, and Mark Painter. For the first time in years, the conversion factor (CF) is set ...
The 2026 AUA Annual Meeting will feature significant bladder cancer data, a plenary lecture on screening and overdetection, and programming that integrates advanced practice providers across sessions, ...
The FDA approved neoadjuvant durvalumab with gemcitabine and cisplatin, followed by adjuvant durvalumab, for muscle invasive bladder cancer (MIBC). Phase 3 NIAGARA trial results showed improved ...
In a retrospective study of almost 500 men, the use of hyaluronic acid filler for penile girth enhancement appeared safe with limited adverse events. Using the PhalloFILL system, a novel hyaluronic ...
5-year results from the pivotal WATER trial showed IPSS improvement was greater with Aquablation compared with TURP. Aquablation therapy demonstrated strong efficacy and safety vs transurethral ...
Cretostimogene grenadenorepvec shows a 24-month complete response rate of 41.8% in high-risk BCG-unresponsive patients with NMIBC, with 90% of 12-month responders maintaining CR. The BOND-003 trial ...
Circulating tumor DNA (ctDNA) is a strong prognostic biomarker in the neoadjuvant setting for muscle-invasive bladder cancer. Perioperative durvalumab with neoadjuvant chemotherapy improves event-free ...
The TRAVERSE trial showed testosterone therapy's MACE risk is non-inferior to placebo, reassuring prescribers and patients. Despite the updated labeling, caution is advised due to potential venous ...
New ASCO GU data compares fluorinated PSMA PET tracers, showing how bladder activity affects detection of prostate cancer recurrence at low PSA. In this episode, ‘Comparative PSMA PET Tracer ...
A 500 mg dose of abiraterone acetate showed comparable efficacy to the standard 1000 mg dose in prostate cancer treatment, with a favorable safety profile. The study demonstrated significant PSA ...
The Visby Medical test is the first at-home, prescription-free diagnostic for chlamydia, gonorrhea, and trichomoniasis. It provides results in approximately 30 minutes using a self-collected vaginal ...
"When determining which code you should use, you must consider your Medicare carrier’s published rules and commercial payer processing policies," write Jonathan Rubenstein, MD, and Mark Painter. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results